公开(公告)号：EP3862348A1

公开(公告)日：2021-08-11

申请号：EP19867602.5

申请日：2019-09-30

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： CHEN, Xiaohua ,  LI, Jia ,  CHENG, Yu ,  ZHOU, Yubo ,  NIE, Huijun ,  WANG, Yujie ,  TIAN, Hongtao ,  KAN, Weijuan ,  MI, Tian ,  HU, Xiaobei ,  ZHOU, Binshan ,  YAN, Kenian ,  XU, Gaoya ,  ZHONG, Yuhua ,  FENG, Lei

IPC分类号： C07D401/14 ,  C07D401/04 ,  C07D413/14 ,  C07D491/107 ,  C07D487/10 ,  C07D498/10 ,  C07D419/14 ,  C07D417/14 ,  C07D409/14 ,  C07D405/14 ,  A61K31/45 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/538 ,  A61P35/00 ,  A61P37/00 ,  A61P25/00 ,  A61P29/00

摘要： The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound is provided in the present invention as a class of novel CRL4 CRBN E3 ubiquitin ligase modulators in structure, wherein same has a stronger antitumor activity and antitumor spectrum, and can be used to prepare drugs for treating CRL4 CRBN E3 ligase-related diseases.